AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD featuring Author Spotlight features Joshua Burshtein MD, one of the co-authors of “Remibrutinib: Insights Into Its Mechanism of Action and Use for Dermatologic Conditions”

Author Spotlight: Joshua Burshtein MD

| Author Spotlight, Featured Articles, Latest News | No Comments
Check Out JDD Corner’s Latest Author Spotlight Our current Author Spotlight features Joshua Burshtein MD, one of the co-authors of “Remibrutinib: Insights Into Its Mechanism of Action and Use for…

Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging and Restores Firmness and Elasticity

| Featured Articles, Latest News, Skincare | No Comments
From the Vault: Prospective single arm study reports sustained gains in firmness and hydration after cell free autologous injections We pulled this article from the JDD vault. A prospective, single…
Journal of Drugs in Dermatology JDD featuring Hydroquinone and Emerging Depigmenting Agents: Clinical Guidelines, Regulatory History, and Global Safety Considerations

Hydroquinone and Emerging Depigmenting Agents: Clinical Guidelines, Regulatory History, and Global Safety Considerations

| Dyspigmentation, Featured Articles, Latest News | No Comments
Rethinking Hydroquinone: A JDD Review Every Dermatologist Should See Did you catch the latest JDD review on hydroquinone? This concise review revisits hydroquinone’s place in treating hyperpigmentation, examining its clinical…

Leave a Reply